So far, the Food and Drug Administration (FDA) has approved three new targeted therapies in AML patients: (a) the antibody-drug conjugate gentuzumab ogozamycin (GO) in relapsing CD33+ AMLs; (b) the tyrosine kinase inhibitor midostaurin in FLT3-ITD-mutated AMLs; (c) the IDH2 inhibitors Enasidernib in IDH2-mutated AMLs [75]. This evidence concerns the gene FLT3 and acute myeloid leukemia.